Search | Clinical Trials Finder

Conditions: Healthy
Interventions: JNJ-70033093, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza
Interventions: mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, SARS-CoV-2
Interventions: mRNA-1083; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 932 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Renal Dialysis, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Chronic Low-back Pain
Interventions: Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT); Other · Drug · Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Physical Inactivity
Interventions: Motor Skills Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 5 Years to 8 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lung Cancer, Adenocarcinoma
Interventions: Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions: Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: Egg breakfast, Egg breakfast with high saturated fat, Cereal breakfast, Cereal breakfast with high saturated fat; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: HIV-1
Interventions: F/TAF, 3rd ARV agent, Boosted PIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more

Conditions: Suicide, Self Harm
Interventions: MI-Enhanced Safety Plan at Hospitalization (1st Component), MI-Enhanced Text Boosters (2nd Component), MI-Enhanced Booster Call (3rd Component); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia
Interventions: Elpipodect, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more

Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions: JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more

Conditions: Healthy Volunteer
Interventions: ABBV-142, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Covid19
Interventions: sotrovimab; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more

Conditions: Asthma
Interventions: electronic medical record, Integrated Approach to Care, usual care, Shared Decision Making, school based care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 1,040 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Charlotte, North Carolina

Conditions: Peripheral Arterial Disease
Interventions: Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF); Behavioral · Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: ZB716, Palbociclib; Drug
Lead sponsor: EnhancedBio USA Inc.; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Mild Cognitive Impairment, Insomnia
Interventions: Multicomponent Behavioral Sleep Intervention for Insomnia, Active Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Celiac Disease
Interventions: Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C; Drug · Other
Lead sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

The CHAMP ASP: Promoting Physical Activity & Health in Children

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

An Adaptive Intervention for Adolescents at Risk for Suicide: A Pilot SMART

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)